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Epicutaneous Immunization with Autoantigenic
Peptides Induces T Suppressor Cells that Prevent
Experimental Allergic Encephalomyelitis
the human disease multiple sclerosis (Goverman and
Brabb, 1996) (MS), an inflammatory attack on the central
nervous system (CNS) that results in extensive demye-
lination and altered neurological functions (Brosnan and
Raine, 1996; Steinman, 2001).
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New Haven, Connecticut 06520 Unlike the MBP-TCR-Tg mouse model, which develops
acute, monophasic EAE, (SJLxPL/J)F1 and (B10.PLxSJL)F1
mice develop spontaneous remissions and relapses that
closely mimic the clinical and pathologic characteristicsSummary
of MS (Dittel et al., 2000; Kuchroo et al., 2002). Thus,
comparison of these different mouse strains treated withInformation on how suppressor/regulatory T cells can
be generated directly in vivo and prevent autoimmunity their specific CNS antigens will help to determine
whether the epicutaneous mode of antigen delivery canremains fragmentary. We show here that epicuta-
neous immunization (ECi) with the immunodominant be potentially beneficial as a putative therapeutic tool
for MS. We therefore epicutaneously immunized (ECi)peptide of myelin basic protein (MBP), Ac1-11, pro-
tects mice that are transgenic for an Ac1-11-specific nontransgenic (B10.PLxSJL)F1 and (SJLxPL/J)F1 mice
with their eliciting peptide antigens, Ac1-11 and proteo-T cell receptor against both the induced and spontane-
ous forms of experimental allergic encephalomyelitis lipid protein (PLP)139-151, respectively. We then at-
tempted to induce disease in order to determine whether(EAE). This protection was antigen specific and anti-
gen dose dependent, and was mediated by CD4/ they can be protected from an initial attack of EAE and
from its spontaneous relapses. In both cases, EAE wasCD25 T cells whose suppressive activity required
cell-cell contact and could transfer protection to naive prevented.
recipients. These ECi-induced suppressor T cells con-
trolled naive MBP-specific CD4 T cells by inhibiting Results
both their activation and their capacity to secrete
IFN-. There was no CD4 T cell infiltration in the brain ECi with Ac1-11 Protects MBP-TCR-Tg Mice from EAE
of protected mice. Finally, ECi with autoantigenic pep- MBP-TCR-Tg mice underwent ECi with Ac1-11 at vary-
tides protected two nontransgenic models from re- ing concentrations (0.1 g–1 mg) or with PBS. After 2
lapsing-remitting EAE in an antigen-specific and anti- weeks, we attempted to induce EAE by subcutaneous (sc)
gen dose-dependent manner. immunization with Ac1-11 in CFA and intravenous injec-
tion of pertussis toxin (see Experimental Procedures).
Introduction All mice ECi with Ac1-11 in a patch prior to EAE induc-
tion showed varying degrees of protection compared to
The route and dose of antigen administration have long PBS ECi controls (Figure 1A). Furthermore, the protec-
been known to be key determinants in the experimental tion was antigen dose dependent. Mice that were ECi
induction of immune activation or of immunological tol- with 10 g of Ac1-11 showed dramatically greater pro-
erance, which might be caused by specific activation tection than those that received 0.1 g, 1 g, 100 g,
of T cells. Recently, epicutaneous (skin) immunization or 1 mg. Not only were the number of mice protected
with protein antigens was shown to induce strong Th2 from EAE significantly higher in the group that received
immune responses in mice (Herrick et al., 2000; Wang 10 g, but the disease onset occurred at a later time
et al., 1996, 1999). These studies employed an occlusive and the disease was less severe (Table 1).
skin patch in which a protein antigen such as ovalbumin To determine whether protection from EAE was anti-
(OVA) was applied to the patch that was then put in gen specific or whether any antigen can suppress EAE
direct contact with the shaved skin of mice. In this study, by some nonspecific mechanism, MBP-TCR-Tg mice
we asked whether the epicutaneous application with were ECi in parallel with varying doses of Ac1-11, OVA,
tissue-specific autoantigenic peptides prior to disease PBS, or other myelin peptides such as myelin oligoden-
induction could interfere with the development of Th1 drocyte glycoprotein (MOG)35-55 or proteolipid protein
cell-mediated responses directed to the same antigen (PLP)139-151, following which we attempted to induce
and thus protect mice from experimental allergic en- EAE. In contrast to mice receiving 10 g Ac1-11, mice
cephalomyelitis (EAE). We applied the myelin basic pro- that received OVA, MOG35-55, or PLP139-155 by the
tein (MBP) peptide, Ac1-11, to the skin of transgenic epicutaneous route developed EAE with identical fre-
mice expressing the Ac1-11-specific MBP  TCR quency and severity (at all concentrations tested: 10
(Hardardottir et al., 1995). EAE can be induced in these g–1 mg; see Supplemental Figure S1 at http://www.
mice, which can also develop spontaneous EAE de- immunity.com/cgi/content/full/19/3/317/DC1) as the
pending on their genetic makeup (Lafaille et al., 1994). PBS ECi control mice (Figure 1B and Table 1A). This
Thus, the MBP-TCR-Tg mouse serves as a model for comparison shows that ECi with Ac1-11 is required to
confer protection from the Ac1-11 peptide-induced EAE.
Therefore, protection cannot be due to some nonspe-*Correspondence: margaret.bynoe@yale.edu
1Deceased. cific mechanism of induction. These data also demon-
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Figure 1. ECi with Ac1-11 Induces Dominant Tolerance in MBP-TCR-Tg Mice
(A) MBP-TCR-Tg mice were ECi with varying doses of Ac1-11: 1 mg, 100 g, 10 g, 1 g, 0.1 g, or PBS.
(B) To determine whether protection is Ac1-11 specific, mice were ECi with Ac1-11 at 10 g, with OVA at 10 g and 100 g concentrations,
with MOG35-55 at 10 g, with PLP139-151 at 10 g, or with PBS for comparison. Note that the same group of mice treated with 10 g of
Ac1-11 per patch is shown in both (A) and (B).
(C) MBP-TCR-Tg mice were ECi with 10 g of Ac1-11 and given anti-IL4, anti-IL-10, anti-TGF- monoclonal antibodies or their isotype-
matched controls, or PBS prior to and during ECi with Ac1-11 as well as after EAE induction.
(D) Irradiated naive B10.PL mice were adoptively transferred with 1  107 total splenocytes from Ac1-11 ECi or naive MBP-TCR-Tg mice
(control group), or cotransferred with cells from both naive and Ac1-11 ECi mice.
(E) Spleen and lymph node cells from Ac1-11 ECi mice are stained with anti-CD4 and the 3H12 clonotypic antibody (top left). Profiles for
sorted CD4/3H12 cells (top right) and naive MBP-TCR-Tg C/ splenocytes (bottom) are also shown.
(F) 1  106 sorted Ac1-11-specific CD4 T cells from Ac1-11 ECi mice or naive MBP-TCR-Tg mice were adoptively transferred into MBP-TCR-
Tg C/ recipients.
strate that applying antigen to the skin prior to EAE els of IL-2 and IFN-, while Ac1-11 ECi mice produced
low to moderate levels of IL-2 and no IFN- in superna-induction protects MBP-TCR-Tg mice from EAE in a
dose-dependent and antigen-specific manner. The ab- tants or sera (discussed later in Figure 4). We next per-
formed cytokine blocking experiments in vivo for IL-4,breviation Ac1-11 ECi will be used to refer to mice that
were ECi with the Ac1-11 peptide and were protected IL-10, and TGF- by administering antibodies to these
cytokines or isotype-matched controls to mice ECi withfrom induced EAE.
10 g Ac1-11. Mice that received anti-cytokine antibod-
ies were protected at the same frequency as mice thatNo Requirement for Th2 Cytokines
received the corresponding isotype-matched immuno-in ECi-Induced Protection
globulin (Figure 1C and Table 2C). This suggests thatTo determine whether the mechanism of protection
IL-4, IL-10, and TGF- may not play a significant role inagainst EAE involved the induction of a Th2 immune
mediating protection from EAE in this system.response in ECi mice, we examined the cytokine profiles
both in mice showing protection and in control mice
that got EAE. We found no significant production of Disease Protection Can Be Transferred to Naive
MBP-TCR-Tg Recipientsthe cytokines IL-4, IL-10, IL-13, or TGF- in sera or in
antigen-stimulated culture supernatants from antigen- We next investigated whether peripheral lymphoid cells
from Ac1-11 ECi mice can suppress EAE induction instimulated CD4 T cells from these mice (data not shown).
However, control MBP-TCR-Tg mice produced high lev- naive MBP-TCR-Tg mice. Splenocytes from Ac1-11 ECi
ECi with Autoantigen Induces T Suppressor Cells
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Table 1. EAE Incidence in Ac1-11 ECi and Control MBP-TCR-Tg Mice
Day of
A. Antigen/Dose n # Mice with EAE # Recovered Disease Onset Mean EAE Score
Ac1-11 1 mg 11 6/11 1/6 8 3.2
Ac1-11 100 g 30 16/30 1/16 8 2.8
Ac1-11 10 g 30 13/30 9/13 15 0.7
Ac1-11 1 g 13 8/13 3/5 14 1.9
Ac1-11 0.1 g 6 5/6 2/5 18 2.5
OVA 100 g 21 17/21 1/17 7 4.3
PBS 18 15/18 0/15 6 4.3
MOG35-55 10 g 11 11 0/11 7 5
PLP139-151 10 g 6 4 0/4 8 4
B. Total Splenocytes (Spcs) or CD4 T Cells from Ac1-11 ECi Mice Can Transfer Dominant Suppression
Spcs Ac1-11 ECi 5 2/5 1/2 18 1.2
Spcs naive Tg 5 5/5 0/5 5 5
Ac1-11 ECi:naive MBP Tg 5 3/5 1/3 10 1.9
CD4 Ac1-11 ECi 9 4/9 1/4 8 2.4
CD4 naive MBP-TCR Ca/ 4 4/4 0/4 5 5
In (A) n refers to number of mice for two to four experiments; in (B) n refers to number of mice for one experiment. Experiments in (B) were
done a minimum of six times with very similar outcomes.
mice or from control naive MBP-TCR-Tg mice were de Keere and Tonegawa, 1998). We therefore hypothe-
sized that CD4 T cells were involved in the suppressiontransferred into sublethally irradiated, naive B10.PL re-
cipients. Five days later, we attempted to induce EAE. of EAE in Ac1-11 ECi mice and that these cells were
Ac1-11 specific (see Figure 1B). CD4 T cells from Ac1-Less than 1 week after EAE induction, the control mice
developed flagrant EAE and all such mice died before 11 ECi (Figure 1E) or naive MBP-TCR-Tg mice, after
being stained and sorted with a clonotypic antibody2 weeks. By contrast, EAE was significantly suppressed
in recipients that were cotransferred with both naive (Figure 1E), were transferred into 4-week-old MBP-TCR-
C/ recipients. The MBP-TCR-C/ mice are devoidMBP-TCR-Tg and Ac1-11 ECi cells, and more so in re-
cipients that received splenocytes only from Ac1-11 ECi of most endogenous CD4 and CD8T cells, so they are
comprised almost entirely of MBP-TCR-Tg CD4 T cellsmice (Figure 1D and Table 1B). Thus, splenocytes from
Ac1-11-ECi mice can protect recipient mice carrying (Figure 1E). The use of these mice allowed us to evaluate
naive MBP-TCR-Tg T cells from EAE. the effect of CD4 T cells on a quasi-pure population of
naive CD4 MBP-TCR-Tg T cells. EAE was induced 5
days after transfer. Mice receiving CD4 T cells from Ac1-Ac1-11-Specific CD4 T Cells Mediate Protection
11 ECi mice show significant protection from EAE: fiveThere are examples where CD4 T cells are involved in
resistance to EAE (Olivares-Villagomez et al., 1998; Van out of nine mice survived, while four out of nine mice
Table 2. CD4CD25 T Cells Confer Protection from Induced EAE
Maximum or Mean # Mice
A. Treatment n Mice with EAE EAE Score Recovered Disease Onset
0.25  106 CD4/CD25 3 3/3 5 0 1 week
0.5  106 CD4/CD25 3 3/3 5 0 2 weeks
1.0  106 CD4/CD25 3 2/3 1 and 1.5 2/2 2.5 weeks
0.25 106 CD4/CD25 3 3/3 5 0/3 2 weeks
0.5  106 CD4/CD25 3 2/3 2.5 and 5 1/2 2.5 weeks
1.  106 CD4/CD25 3 1/3 1 1/3 2.5 weeks
B. Cells from Ac1-11 EC-sp Mice but Not Controls Protect MBP-TCR-C/ Mice from Spontaneous EAE
Ac1-11 10 g 5 3/5 4 1/3 3.5 months
PBS 5 5/5 5 0/5 7 weeks
CD4 T cells from Ac1-11 ECi mice 5 0/5 0 N/A None up to 7 months
CD4 T cells from PBS ECi mice 5 4/5 4 0/4 3 months
C. In Vivo Anti-Cytokine Treatment in Mice ECi with Ac1-11
Anti-IL-4 5 2 1.6 1 9 days
Anti-IL-4 control (rat Ig) 4 1 1.25 0 12 days
Anti-IL-10 5 3 1.3 2 8 days
Anti-IL-10 control (mouse Ig) 5 4 1.6 3 8 days
Anti-TGF- (1,2,3) 5 1 1 0 8 days
Anti-TGF- control (mouse IgG1) 5 1 0.8 1 6 days
In (A)–(C), n refers to the number of mice per experimental group for one experiment. Mean EAE score refers to (C). Experiments in (B) were
done two to four times and in (A) three times with similar outcomes.
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developed EAE and died. By contrast, all control mice above. Naive MBP-TCR-Tg cells proliferated similarly
with or without the addition of naive nontransgenic CD4died from EAE within a few days of disease induction
(Figure 1F and Table 1B). These data show a role for T cells (Figure 2D). We conclude that ECi induced anti-
gen-specific CD4 T cells able to suppress the activationantigen-specific CD4 T cells in protection against EAE
and demonstrate that tolerance induced by ECi with of Ac1-11 specific naive CD4 T cells in response to
cognate stimulation.Ac1-11 is dominant, as protection can be transferred to
naive MBP-TCR-Tg recipients. We therefore refer to CD4
T cells isolated from Ac1-11 ECi mice as suppressor Suppression by Ts Cells Is Contact Dependent,
T cells (Ts). but Independent of IL-4, IL-10, and TGF-
We next performed in vitro Th2 cytokine blocking experi-
ments to determine whether antibodies to IL-4, IL-10,Protection against EAE Does Not Depend
on CD4CD25 T Cells or TGF- can inhibit the suppression of naive MBP-
TCR-Tg CD4 T cell proliferation. As shown in Figure 2E,There is strong evidence that the CD4CD25 T cell
subset confers protection in a variety of organ-specific suppression of naive MBP-TCR-Tg T cell proliferation in
vitro was not blocked by anti-cytokine mAbs treatment.autoimmune disease models (Sakaguchi et al., 1995;
Salomon et al., 2000; Shevach, 2001). To examine This result is fully consistent with the in vivo data and
indicates that IL-4, IL-10, or TGF- cytokines did notwhether CD4CD25 T cells are involved in protection
against EAE in our model, we sorted CD4CD25 and play any significant role in disease suppression. To de-
termine whether contact between effector T cells andCD4CD25 cells from pooled spleens and lymph nodes
of Ac1-11 ECi mice. These subsets were adoptively Ts cells is necessary for suppression to occur, we per-
formed transwell-based assays in which Ts cells weretransferred into young naive MBP-TCR-C/ recipi-
ents. We then attempted to induce EAE 5 days later. All separated or not separated from effector cells in the
presence of APCs and antigen. The results show defini-recipient mice that received less than 1  106
CD4CD25 T cells developed EAE and died. Recipients tively that Ts cells need to be in contact with effectors
and/or APCs for suppression to occur (Figure 2F).that received 0.5  106 and 1  106 CD4CD25 T cells
developed less severe EAE (Figure 2A and Table 2A).
Therefore, CD4CD25 T cells are sufficient to confer ECi with Ac1-11 Can Suppress Spontaneous EAE
protection from EAE. Furthermore, CD4CD25 T cells We asked whether ECi with Ac1-11 could protect MBP-
show a somewhat greater degree of suppression than TCR-C/ mice from spontaneous EAE. As explained
CD4CD25T cells, as protection was observed at lower above, T cells in these mice are comprised almost en-
cell numbers than that observed by transferring tirely of MBP-TCR-Tg CD4 T cells (Figure 1E). Therefore,
CD4CD25 cells. It is worth noting that the CD4CD25 similar to RAG/ mice, they develop spontaneous EAE
subset never represented more than 5% of the CD4 by 6 weeks of age (Lafaille et al., 1994; Olivares-Villago-
T cell population in the Ac1-11 ECi mice (data not mez et al., 1998). Naive MBP-TCR-C/ mice were ECi
shown). with 10 g Ac1-11. Disease onset occurred at 7 weeks
in control mice, and by 4.5 months, all such mice had
developed EAE and died (Figure 3A and Table 2B). InCD4 T Cells from ECi Mice Are Unresponsive
and Inhibit Proliferation of Effector Cells contrast, the first symptoms of EAE developed in Ac1-
11 ECi mice at 3.5 months and some mice did not devel-We next assessed the proliferative capacity of CD4
T cells from Ac1-11 ECi mice, along with control mice op EAE (Table 2B). Hence, ECi with Ac1-11 can protect
MBP-TCR-C/ mice from spontaneous EAE. Thesewith a clinical score of 3.5. These were compared with
cells from naive MBP-TCR-Tg mice to determine their mice will be referred to as Ac1-11 ECi-sp.
We next asked whether CD4 T cells from Ac1-11 ECi-ability to proliferate. Cells from Ac1-11 ECi mice prolifer-
ated less efficiently and produced little to no IL-2 as sp mice could protect against induced EAE. CD4 T cells
from Ac1-11 ECi-sp or control mice were transferred tocompared to both control and naive mice, which indi-
cates varying degrees of unresponsiveness (Lechler et MBP-TCR-C/ recipients prior to EAE induction. The
onset of EAE was the same in both groups, and theal., 2001) (Figure 2B). To determine whether the unre-
sponsiveness could be restored by IL-2, we treated CD4 control mice died in less than 1 week. Recipients with
cells from Ac1-11-ECi-sp mice showed a significant lagT cells from Ac1-11 ECi mice with exogenous IL-2 and
antigen. There was a 2-fold increase in proliferation in in disease of 30 days, and by 35 days all mice had died
(Figure 3B). This is in contrast with the above data inthe presence of IL-2 and antigen (Figure 2C). IL-2 without
antigen did not induce proliferation. We then asked Figure 1E where CD4 T cells from Ac1-11 ECi mice al-
most totally inhibited the development of induced EAE.whether these Ts cells can suppress the proliferation of
naive CD4 T cells in vitro, as previously reported (Chai These data imply that immunization with Ac1-11 in CFA,
after ECi with Ac1-11, is required to generate dominantet al., 1999). Naive MBP-TCR-Tg CD4 T cells were cocul-
tured with CD4 Ts cells at various cell ratios. Ts cells suppression (or Ts).
Earlier, we showed that CD4 T cells from Ac1-11 ECiinhibited the proliferative response of naive MBP-TCR-
Tg T cells in a cell dose-dependent manner. To deter- mice suppressed induced EAE development (Figure 1F).
We also investigated whether these same CD4 T cellsmine whether this was indeed suppression and not sim-
ply inhibition of proliferation due to competition for can protect against spontaneous EAE. Sorted CD4
T cells from pooled spleen and lymph nodes from Ac1-11space or access to APCs, we cocultured naive CD4
T cells from MBP-TCR-Tg mice with CD4 T cells from ECi mice or naive MBP-TCR-C/mice were adoptively
transferred into naive MBP-TCR-C/ recipients. Dis-naive nontransgenic mice at the same cell ratios as
ECi with Autoantigen Induces T Suppressor Cells
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Figure 2. Ts Cells Suppress Effector Cell Proliferation by Cell-to-Cell Contact and Are Functionally Altered
(A) MBP-TCR-Tg C/ mice were adoptively transferred with varying doses of sorted CD4CD25 T cells (0.25  106 [open square], 0.5 
106 [open triangle], 1  106 [open circle]) or CD4CD25 T cells (0.25  106 [closed square], 0.5  106 [closed triangle], 1  106 [closed circle])
from Ac1-11 ECi mice and monitored for EAE.
(B) Sorted CD4 T cells from various Ac1-11 ECi mice (closed triangle, closed diamond, closed square, open circle), naive MBP-TCR-Tg mice
(open triangle), or mice with end-stage EAE (closed circle) were stimulated in vitro with Ac1-11 to determine their proliferation status.
(C) Sorted CD4 T cells from Ac1-11 ECi (open circle) or naive MBP-TCR-Tg mice (closed square) were cultured with APCs and varying
concentrations of Ac1-11 alone; CD4 T cells from Ac1-11 ECi mice were also cultured with APCs, and fixed Ac1-11 (10 g/ml), and varying
concentrations of IL-2 (closed triangle).
(D) Sorted CD4 T cells from Ac1-11 ECi mice, when cocultured with naive MBP-TCR-Tg T cells in the presence of peptide and APCs, could
suppress naive MBP-TCR-Tg CD4 T cell proliferation in vitro in a dose-dependent manner.
(E) Varying concentrations of anti-IL-4, anti-IL-10, anti-TGF- mAbs, and their corresponding isotype-matched controls did not block the Ts
cell-mediated suppression of naive CD4 T cell proliferation in the presence of fixed numbers of APCs, Ts cells, and antigen in vitro.
(F) In a transwell assay, various numbers of Ts cells were cultured directly with fixed numbers of APCs, effector cells, and antigen (closed
circle), or separated from effector cells by a membrane (closed diamond). No inhibition was observed when Ts cells were separated from
effector cells, and inhibition was specific to Ts cells as CD4 T cells from nontransgenic littermates (open triangle) showed no inhibition of
proliferation.
ease onset occurred at 3 months in control mice and also develop RR-EAE by immunization with Ac1-11 in
CFA (Dittel et al., 2000). We ECi (SJLxPL/J)F1 mice withby 4 months, four of the five mice died while one mouse
remained free of EAE symptoms. All recipients that re- varying doses of PLP139-151 or with OVA, PBS, or
ceived cells from Ac1-11 ECi mice were without any MOG35-55 as controls, after which we induced disease
clinical signs of EAE at 7 months (Figure 3C and Table with PLP139-151 in CFA. (B10.PLxSJL/J)F1 mice were
2A). Thus, CD4 T cells from Ac1-11 ECi mice can sup- ECi with 10 or 100 g Ac1-11 or with MOG35-55 as
press spontaneous disease. control. Complete protection was observed in mice that
were ECi with 1 mg/ml of PLP139-151; mice that were
ECi with 100 or 10 g PLP139-151 had the same timeECi with Autoantigen Can Protect Mice
of disease onset as control mice. However, disease wasfrom Relapsing-Remitting EAE
much less severe in mice that were ECi with 100 gIn (SJLxPL/J)F1 mice, relapsing-remitting EAE (RR-EAE)
PLP139-151 when compared to the 10 g group; bothcan be induced by immunization with the immunodomi-
of these groups developed significantly less severe dis-nant peptide of proteolipid protein (PLP)139-151 in CFA
(Karandikar et al., 1998). The (B10.PLxSJ/L)F1 mice can ease as compared to the controls. This same pattern
Immunity
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Figure 3. ECi with CNS Antigens (Ac1-11, PLP139-151) Suppress Spontaneous and R-R-EAE
(A) Four- to six-week-old MBP-TCR-Tg C/ mice when ECi with Ac1-11 show substantial protection from spontaneous EAE when compared
to PBS controls.
(B) Pooled spleen and lymph node cells collected 5.5 months after ECi from Ac1-11 ECi-sp mice (closed symbol) or from control mice (open
symbol) were adoptively transferred into naive MBP-TCR-Tg C/ recipients, and EAE was induced.
(C) CD4 T cells from Ac1-11 ECi mice (closed symbol) or from naive MBP-TCR-Tg C/ mice (open symbol) were transferred into naive MBP-
TCR-Tg C/ recipients that were monitored for spontaneous disease.
(D) (SJL x PLJ)F1 mice were ECi with varying doses of PLP139-151 peptide. As controls, mice were ECi with OVA, PBS, or MOG135-155
peptide, another CNS antigen.
(E) (B10.PL x SJL)F1 mice were ECi with Ac1-11 at 100 g, 10 g, or OVA as control.
(F) Representative MHC class II/CD11c distribution for epidermal APCs prepared after epicutaneous immunization.
(G) Epidermal APCs from mice ECi with Ac1-11 or Ac1-11-CFA were incubated with naive antigen-specific CD4 T cells. CD4 T cells were
reisolated prior to stimulation with Ac1-11 and fresh APCs.
(H) APCs from skin-draining lymph nodes of mice that were ECi with Ac1-11, Ac1-11-CFA, or PBS were cultured with naive antigen-specific
CD4 T cells without exogenous antigen.
(I) APCs from skin-draining lymph nodes of Ac1-11-CFA ECi mice were cultured with naive antigen-specific CD4 T cells and Ac1-11 plus anti-
MHC class II (Y3JP) mAb or isotype control.
was observed in the spontaneous relapse phase of the was seen at both peptide (Ac1-11) concentrations (10
and 100 g). Mice that were ECi with 100 g of Ac1-11disease (Figure 3D and Table 3).
In the (B10.PLxSJL/J)F1 mice, significant protection never developed disease; one mouse in the 10 g group
Table 3. ECi with Their Cognate Antigens Protected (SJLxPLJ)F1 and (B10.PLxSJL)F1 Mice from R-R-EAE
# Mice # Mice Days of Mean Initial # Mice Relapsed
Mouse Strain Antigen/Dose n with EAE Recovered EAE Onset EAE Score 1st/2nd
(SJLxPLJ)F1 PLP139-151/10 g 15 7 5 11 1.2 2/2
(SJLxPLJ)F1 PLP139-151/100 g 10 3 3 13 0.4 1/1
(SJLxPLJ)F1 PLP139-151/1 mg 5 0 0
(SJLxPLJ)F1 MOG35-55/10 g 5 5 4 9 2.3 2/3
(SJLxPLJ)F1 OVA/100 g 5 5 4 10 2.6 3/3
(SJLxPLJ)F1 PBS 10 10 8 10 3 5/3
(B10.PLxSJL)F1 Ac1-11/10 g 4 1 1 16 0.5 0/0
(B10.PLxSJL)F1 Ac1-11/100 g 3 0 0
(B10.PLxSJL)F1 MOG35-55/10 g 5 5 2 11 3.8 2/2
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developed mild disease, fully recovered, and did not mice displayed a background response. This showed
that Ac1-11 was effectively captured by skin dendriticrelapse over the 60 days of disease monitoring. Control
mice developed fulminant EAE: three out of five mice (Langerhans) cells in ECi mice and carried to the draining
lymph nodes (Figure 3H). This proliferation was specificdied and the other two relapsed (Figure 3E and Table
3). These data confirmed that ECi with autoantigenic as it could be neutralized by addition of anti-MHC class
II (Y3JP) antibody (Figure 3I). From these data, and frompeptide can protect different strains of mice both from
the primary disease and the relapses that follow in an the data showing that mice ECi with peptide  CFA are
not protected from EAE, we infer that the epicutaneousantigen dose-dependent and antigen-specific manner.
Additional studies indicated that CD4 T cells from delivery of antigen in the absence of adjuvant (i.e., ab-
sence of costimulatory signal induction) affects theprotected (B10.Pl x SJL)F1 mice displayed characteris-
tics similar to those of Ts cells from the MBP-TCR-Tg priming of naive antigen-specific T cells and alters their
functionality.mouse model. They were unresponsive to stimulation
with their cognate peptide (Ac1-11) in vitro (see Supple-
mental Figure S2 at http://www.immunity.com/cgi/
Ts Cells Suppress the Secretion of IFN- by Effectorcontent/full/19/3/317/DC1), they did not produce IL-4, IL-
Cells Both In Vitro and In Vivo10, IL-13, or TGF- cytokines upon stimulation (data
We have consistently found IFN- present in the seranot shown), and they could suppress responder cell
of MBP-TCR-Tg mice with active EAE followed by aproliferation in vitro (Supplemental Figure S3). There was
concomitant rise in IFN- titer as disease progressed.also no change in the frequency of CD4CD25 T cells
This is in contrast to healthy or naive MBP-TCR-Tg miceupon ECi and during long-term protection in both
that do not produce any substantial level of IFN- in(B10.PL x SJ/L)F1 and (SJL x PL/J)F1 mice. Thus, ECi-
their sera. We examined pooled sera of Ac1-11 ECi miceinduced protection could operate in relapsing-remitting
or controls for the presence of IFN- prior to (week 0)models of EAE and is therefore not restricted to the
and during ECi (weeks 1 and 2) and post-EAE inductionMBP-TCR-Tg model.
(weeks 3–6). Only mice with progressive EAE produced
any substantial amount of IFN- in their sera that in-
Epidermal Antigen-Presenting Cells Influence creased with disease severity. There was no significant
the Priming of Naive CD4 T Cells level of IFN- present in sera of Ac1-11 ECi mice (Figure
We explored the possibility that, in ECi mice, epidermal 4A). Similar observations were made in tissue culture
dendritic cells may play a role in the induction of Ts cells. supernatants from antigen-stimulated CD4 T cells from
Subsequent to epicutaneous application, the antigen Ac1-11 ECi mice. This is compared to high IFN- levels
may be gradually and continuously presented to anti- produced by naive CD4 T cells or CD4 T cells from mice
gen-specific CD4 T cells in skin-draining lymph nodes. with active disease after being stimulated with antigen
Due to the absence of adjuvant, such presentation could in vitro (Figure 4B). To further test the effect of Ac1-11
impair the functionality of naive T cells. In experiments ECi on IFN- production in MBP-TCR-Tg mice, we
where MBP-TCR-Tg mice were ECi with Ac1-11 in CFA, tested IFN- levels in supernatants from cultures in
we found that mice were clearly not protected from EAE which Ts cells suppressed the proliferation of naive anti-(see Supplemental Table S1). We then isolated antigen- gen-stimulated CD4 T cells. Ts cells suppressed IFN-presenting cells from the epidermis of mice that were secretion by effector cells at least 2-fold (Figure 4C).
ECi with Ac1-11 alone or Ac1-11 in CFA for 30 min to This is strong evidence that ECi-induced Ts cells directlyan hour. As shown by FACS analysis, the vast majority impair the Ac1-11-inducible secretion of IFN- by naive
of such cells expressed MHC class II and CD11c on Ac1-11-specific CD4 T cells.
their surface (Figure 3F). We incubated these APCs in
the presence of naive MBP-TCR-Tg CD4 T cells without
exogenous antigen. We could detect a weak prolifera- Lack of CD4 T Cell Infiltration in the Brain Parenchyma
of Ac1-11 ECi-Protected Micetion only in the presence of epidermal APCs from Ac1-
11  CFA ECi mice (data not shown). We also analyzed EAE is characterized by the infiltration of autoreactive
CD4 T cells into the CNS (Brosnan and Raine, 1996;CD4 T cells after reseparating them from the epidermal
APCs. The reisolated CD4 T cells were incubated with Goverman, 1999). To ascertain whether CD4 T cells from
Ac1-11 ECi mice can infiltrate the CNS, we stained serialfresh irradiated APCs and varying concentrations of
Ac1-11. As shown in Figure 3G, CD4 T cells that were brain sections from perfused mice using anti-CD4
monoclonal antibody (Baron et al., 1993). Brains frompreincubated with epidermal APCs from Ac1-11 ECi
mice failed to proliferate upon stimulation. By contrast, young naive and diseased immunized mice (clinical EAE
score  1.5 and 3) were stained as controls. InfiltrationCD4 T cells that were preincubated with epidermal APCs
from Ac1-11-CFA ECi mice proliferated robustly. We by CD4 T cells was seen only in the brain of the diseased
mice, whereas no infiltration was seen in the perivascu-also analyzed APCs collected from skin draining (super-
ficial inguinal and/or axillary) lymph nodes from freshly lar regions or in the parenchyma of the brains of Ac1-
11 ECi, Ac1-11 ECi-sp, or naive mice (Figures 4Da, 4Db,ECi mice for their ability to stimulate naive antigen-spe-
cific CD4 T cells without the addition of exogenous anti- and 4Dc, respectively, and summarized in Figure 4E).
Therefore, the lack of disease symptoms observed ingen. Remarkably, naive antigen-specific CD4 T cells in-
cubated with lymph node-derived APCs from mice ECi Ac1-11 ECi mice correlates with the lack of CD4 T cell
infiltration in the brain. This is well in line with the datawith Ac1-11-CFA showed a detectable proliferation
while antigen-specific CD4 T cells incubated with lymph showing that Ts cells preempt the activation of naive
Ac1-11-specific CD4 T cells. Altogether the data indicatenode-derived APCs from Ac1-11 ECi or PBS-treated
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Figure 4. Ts Cell-Mediated Suppression of
IFN- Secretion by Naive CD4 T Cells and
Lack of CD4 T Cell Infiltration in the Brain
Parenchyma of Disease-Resistant Mice
(A) Sera from disease resistant (Ac1-11 ECi),
diseased (EAE), and unmanipulated (naive)
mice were tested for the presence of IFN-
by ELISA prior to (week 0) and during ECi
(weeks 1–2) as well as after EAE induction
(weeks 3–6).
(B) CD4 T cells from protected (Ac1-11 ECi)
mice, normal MBP-TCR-Tg (naive) mice, or
mice with active (score 1–3.5) EAE were stim-
ulated in vitro with Ac1-11, and the superna-
tants were tested for IFN- production by
ELISA. Three mice were analyzed in each
group.
(C) ELISA measurement of IFN- production
in supernatants obtained from cultures in
which Ts suppressed the proliferative re-
sponse of naive MBP-TCR-Tg T cells to cog-
nate stimulation.
(D) No CD4 T cell infiltration is detectable in
the brain parenchyma of protected mice by
immunohistochemistry. Sections of perfu-
sion-fixed brain tissue from Ac1-11 ECi mice
protected from spontaneous EAE (a), induced
EAE (b), naive mice (c), and mice with clinical
signs of EAE (score of 1.5 [d] and 3 [e]).
(E) Detailed summary of histological analysis.
that Ts cells act on the induction phase of the disease or unresponsive to cognate stimulation and therefore
and not by controlling autoreactive T cells in the CNS. appeared functionally inactivated. Such a state of unre-
sponsiveness is consistent with the assumption that,
under the conditions used, Ac1-11 is gradually and con-Discussion
tinuously captured by skin resident dendritic (Langer-
hans) cells (Cumberbatch et al., 2000), which in the ab-Epicutaneous immunization with protein or peptide anti-
sence of adjuvant do not acquire their high stimulatorygens in the absence of adjuvant can generate Th2 im-
potential (Linsley and Ledbetter, 1993; Ragazzo et al.,mune responses (Herrick et al., 2000; Wang et al., 1996,
2001; Wulfing and Davis, 1998). Ac1-11 applied to the1999). We reasoned that the delivery of autoantigenic
epidermis could be captured and transported to drainingpeptide through the skin could interfere with the devel-
lymph nodes because APCs derived from skin-drainingopment of inflammatory autoimmune diseases where
lymph nodes of ECi mice could induce a detectable andTh1 cells play a central role (King and Sarvetnick, 1997).
specific proliferation of naive MBP specific CD4 T cells.We observed that the simple epicutaneous application
APCs derived from epidermal cell preparations differedof the Ac1-11 peptide effectively protects MBP-TCR-Tg
in their capacity to stimulate naive CD4 MBP-TCR-Tgmice and MBP-TCR-C/ mice from developing in-
T cells depending on whether they were isolated fromduced and spontaneous EAE, respectively. Disease
mice epicutaneously exposed to autoantigen alone orsuppression was mediated by CD4 T cells because the
to autoantigen plus adjuvant. Further, exposure to epi-adoptive transfer of sorted CD4 T cells from protected
dermal CD11c MHC class II cells from Ac1-11 ECimice was sufficient to protect naive syngeneic recipients
mice clearly converted naive MBP-TCR-Tg CD4 T cellsfrom developing disease.
into T cells unresponsive to cognate stimulation. NotRelative to naive MBP-TCR-Tg CD4 T cells, CD4
T cells able to confer protection were poorly responsive surprisingly, Ac1-11-CFA-ECi MBP-TCR-Tg mice were
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not protected from EAE induced by immunization. In- on the ECi-induced protection from disease. In vitro
suppression was unaffected as well.stead, the onset of the clinical signs of disease was
It has been shown that delivery of antigen throughsignificantly accelerated in these mice (see Supplemen-
the intestinal mucosa could either recruit (Zhang et al.,tal Table S1).
2001) or generate (Thorstenson and Khoruts, 2001)CD4 T cells from Ac1-11 ECi mice were capable of
CD4CD25 T cells with immunosuppressive proper-inhibiting both the proliferation of, and the IFN- secre-
ties. However, we observed that ECi had no positivetion by, naive CD4 MBP-TCR-Tg T cells in response
impact on the representation of the CD4CD25 T cellto Ac1-11 stimulation in vitro. This inhibition required
pool in mice that were protected against EAE by ECi.direct contact with effector cells and did not rely on
In addition, sorted CD4CD25 T cells alone could sup-killing as similar numbers of living cells were recovered
press induced EAE upon adoptive transfer and, on ain the presence of CD4 T cells from protected mice or
per cell basis, were more potent in doing so thanof control CD4 T cells (data not shown). Together with
CD4CD25 T cells. We conclude that there was nothe protective effect observed in transfer experiments,
greater dependence on CD4CD25 T cells than onthese results indicate that the epicutaneous delivery of
CD4CD25 cells in the disease resistance conferred byAc1-11 to Tg mice expressing the Ac1-11-specific MBP-
the Ts cells generated by ECi with Ac1-11. SuppressiveTCR generates CD4 T cells with inhibitory activity. We
activity among CD4CD25 T cells has indeed beenbelieve that the induced inhibitory cells are best de-
reported both in mice and rat (Annacker et al., 2000;scribed by the term “suppressor T cells” (Ts), which was
Apostolou et al., 2002; Stephens and Mason, 2000).first coined by Gershon and coworkers to emphasize
Most interestingly, the naturally occurring CD4 T cellthe negative side of the immunoregulatory potential of
population able to protect MBP-TCR-Tg mice fromT lymphocytes (Gershon and Kondo, 1971; Hu et al.,
spontaneous EAE is itself characterized by the CD251983; Ptak et al., 1983).
phenotype (Olivares-Villagomez et al., 2000).At least two major mechanisms might account for the
During the course of transfer experiments, we noticedabsence of clinical symptoms in Ac1-11 ECi MBP-TCR-
that CD4 T cells from Ac1-11 ECi mice could fully protectTg mice. First, MBP-TCR-Tg T cells could acquire a
naive recipients from both spontaneous and inducedpathogenic potential upon immunization and traffic to
EAE. Although CD4 T cells from Ac1-11 ECi-sp micethe CNS but not cause lesions due to in situ control by
also fully protected against spontaneous disease, theycells with inhibitory activity (Brabb et al., 2000). Alterna-
only transiently reduced disease severity upon activetively, suppression could occur early in the periphery
induction. Possibly, these results could be describedand preempt the differentiation of pathogenic T cells.
by a model where ECi with Ac1-11 induces naive CD4Our histological results definitively ruled out the first
T cells to adopt a presuppressor state that is convertedhypothesis; there were neither mild tissue lesions nor
into a dominant suppressor state upon immunizationCD4 T cell infiltration in the CNS of disease-resistant
with antigen, adjuvant, and pertussis toxin.mice. In addition, there was no deficiency in the expres-
Although EAE developing in the MBP-TCR-Tg mousesion of the VLA-4 homing molecules known to be crucial
shares many characteristics with MS in humans, thefor the migratory capacity of pathogenic MBP-TCR-Tg
absence of spontaneous relapses limits their utility as aT cells (Baron et al., 1993) in these mice (data not shown).
model for elucidating the full scope of MS pathogenesis.These observations imply that under our experimental
Another important feature is the lack of a normal orconditions Ts cells generated by ECi protect mice from
physiologic T cell repertoire; greater than 95% of CD4developing disease by interfering with the priming of
T cells in this mouse model bears the same TCR specific-naive MBP-specific T cells in lymphoid organs. The ex-
ity. In this paper, we also demonstrate that ECi withperimental support for this conclusion is 2-fold. First,
autoantigen is not limited to the MBP-TCR-Tg mouseas mentioned above, purified CD4 T cells from disease-
model, as we can protect against EAE in mouse models
resistant mice had the capacity to block the specific
with a diverse T cell repertoire. For instance, the epicuta-
activation (proliferative response and IFN- secretion)
neous application of the immunodominant peptide of
of purified naive MBP-TCR-Tg CD4 T cells in vitro. Sec- PLP (139-151) protected unmanipulated (SJL x PL/J)F1
ond, in sharp contrast with control mice developing clini- mice from relapsing-remitting EAE. This protection, like
cal signs of EAE, we could not detect the Th1 cytokine that observed in the MBP-TCR-Tg mouse, was antigen
IFN- in the serum or in culture supernatant of cells from specific and antigen dose dependent. In contrast with
disease-resistant mice. The in vivo CD4 T cell-mediated the MBP-TCR-Tg mouse model, maximum protection
suppression we observed is therefore fundamentally was observed at higher peptide concentrations in both
distinct from regulatory mechanisms able to control CD4 the (SJL x PL/J)F1 and (B10.PL x SJL/J)F1 hybrids. Pro-
T cells in situ after they have crossed the blood-brain tection was observed both against the initial disease
barrier (Brabb et al., 2000). phase and in spontaneous relapses. Thus, ECi with au-
We repeatedly failed to detect significant secretion toantigen prior to disease induction protects genetically
of the anti-inflammatory cytokines IL-4, IL-10, IL-13, or unmanipulated mice from both primary and recurrent
TGF- by Ts cells by ELISA upon specific stimulation or disease.
in suppression assays in vitro. Molecular analysis such The influence of antigen dose and route of delivery
as RPA also failed to show significant increase in cyto- has been shown to be a key variable in inducing immune
kine transcript levels in these cells (data not shown). tolerance (Weiner, 2001). Ac1-11 at 10 g on a skin
Consistent with this was the fact that the infusion of patch resulted in the highest level of protection, while
monoclonal antibodies able to neutralize IL-4, IL-10, and higher (100–1 g) and lower doses (0.1–1 mg) of peptide
on the skin patch resulted in more limited protection.TGF- in vivo appeared to have no significant impact
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T Cell Proliferation, Suppression, Anti-IL-2 Treatment,The converse is true in the (SJL x PL/J)F1 and (B10.PL x
and Transwell ExperimentsSJL/J)F1 mice. It is possible that in the MBP-TCR-Tg
Sorted CD4 T cells from spleen and lymph nodes of naive MBP-mouse, high antigen concentrations could potentially
TCR-Tg mice were plated at 5  104cells/well in the presence of
induce a number of MBP-TCR-specific CD4 T cells to 2  105 irradiated B10.PL spleen cells/well as antigen-presenting
differentiate into effector cells. Antigen doses lower than cells in Click’s EHAA medium (Life Technologies) supplemented
with 5% fetal calf serum. Ac1-11 (1–10 g/ml) alone or with IL-210 g may be too small for efficient induction of Ts to
(1–100 U/ml) with fixed concentration of Ac1-11 (10 g/ml) wasoccur, perhaps because of the vast excess of MBP-
added to the cultures. After 48 hr at 37	C, cells were pulsed withTCR-Tg CD4 T cells. Therefore, the majority of MBP-
1 Ci of [3H]thymidine, harvested 18–24 hr later, and counted in aTCR-Tg CD4 T cells could remain naive, become patho-
 plate scintillation counter. To determine whether CD4 T cells from
genic upon immunization, and cause EAE. Conversely, Ac1-11 ECi mice can suppress the proliferation of naive CD4 T cells
the number of potentially autoreactive pathogenic T cells from MBP-TCR-Tg mice, various numbers of CD4 T cells from Ac1-
11 ECi mice or CD4 T cells from nontransgenic mice (controls) wereis rather small in nontransgenic models relative to the
cocultured with a fixed number of naive MBP-TCR-Tg CD4 T cellsMBP-TCR-Tg mouse model, and induction of suppres-
(5 104). 2 105 irradiated APCs were added, and a fixed concentra-sor cells may require a higher concentration of antigen.
tion of Ac1-11 (5 g/ml) was used for stimulation. Culture conditionsIn summary, we have demonstrated that ECi with a
were as described above. Transwell assays were done in 24-well
tissue-specific self-peptide can fully protect mice from plates (Costar, Cambridge, MA) with fixed numbers of effector cells,
developing an autoimmune response driven by CD4 APCs, and Ac1-11 (5 g/ml) in the presence or absence of varying
numbers of Ts or nontransgenic CD4 T cells as control.T cells specific for the same determinant. Disease resis-
tance was mediated by induced CD4 suppressor T cells.
Adoptive TransferThe induced protection was not dependent on engage-
Total splenocytes (pooled spleen and lymph node cells) from naivement/recruitment of CD4CD25 T cells, and it could
(control) or Ac1-11 ECi mice were washed in sterile PBS two tooperate against both spontaneous and induced disease.
three times, and 1  107 cells were resuspended in a final volume
We also demonstrated that the epicutaneous applica- of 200 l PBS and administered intravenously to irradiated (600
tion of CNS antigens to nontransgenic mice can fully rads), naive B10.PL mice 1 day after irradiation. EAE was induced
5 days after transfer. CD4 T cells were stained with the clonotypicprotect them from primary EAE and from spontaneous
antibody 3H12 and sorted. 1 106 Ac1-11-specific CD4 T cells wererelapses. Collectively, these findings may help in the
also resuspended in 200l of PBS and administered intravenously todesign of new, noninvasive therapies to prevent or to
MBP-TCR-C/ recipients. EAE was induced 5 days after transfer.treat chronic inflammatory autoimmune disorders such
as multiple sclerosis, type 1 diabetes, and rheumatoid Tissue Preparation and Immunohistochemistry
arthritis. Mice were perfused and their fixed brains and spinal cords removed
and prepared exactly as described (Baron et al., 1993). Immuno-
staining was performed on 8 m sections with biotinylated anti-
Experimental Procedures CD4 monoclonal antibody as primary antibody.
Mice
Antibodies and FACS Sorting
MBP-TCR/ transgenic mice (MBP-TCR-Tg) express the re-
Cells were stained with anti-CD4-FITC conjugate or anti-CD4-PE
arranged genes encoding the  (V4) and  (V8.2) chains of an
(Caltag, Burlington, CA), anti-mouseV8.1/2-FITC or PE (Phar-
autoreactive, I-Au-restricted TCR specific for the N-terminal acet-
mingen, San Diego, California, USA), and/or anti-CD25-PE or with
ylated peptide (Ac1-11) of MBP (Hardardottir et al., 1995). MBP-
anti-clonotypic antibody, 3H12 (a kind gift from Dr. Juan Lafille).
TCR-Tg mice were mated to TCR-C/ mice to generate MBP-
Anti-MHC class II antibody (Y3JP) was prepared by our laboratory;
TCR-C/ mice. (SJLxPLJ)F1 female mice 4–6 weeks old, and
anti-CD11c-FITC mAb was purchased from Pharmingen. The cells
B10.PL (H2u) mice were purchased from the Jackson Laboratory
were incubated at 4	C for 30 min before being washed and were
(Bar Harbor, ME). (B10.PLxSJL)F1 mice were generated by crossing
then sorted on a FACstar plus. Sorted cells were analyzed on a
SJL with B10.PL. All mice are housed in the pathogen-free facility
FACSscan analyzer (Beckton Dickinson). IL-2, anti-IL-4 (11B11),
at Yale University, New Haven, CT.
anti-IL10 (SXC1), and anti-I-Au (Y3JP) were all produced by our labo-
ratory. Anti-TGF- (1, 2, 3; clone # 1D11) was purchased from
R&D systems (Minneapolis, MN). Biotinylated anti-CD4 was pur-Epicutaneous (Skin) Patch Immunization and EAE Induction
chased from Caltag. CD4 T cells were isolated from skin-drainingThe backs of mice were shaved with an electric razor after being
lymph node preparation using goat anti-mouse IgM, goat anti-Ratlightly anaesthetized with methoxyflurane (Schering-Plough, Union,
IgG, and goat anti-mouse IgG magnetic beads (Qiagen, Hilden, CA)NJ). One day later, Ac1-11 or PLP139-151 (0.1 g/ml to 1 mg/ml) in
as per manufacturer’s protocol.100 l PBS was applied to the gauze on an occlusive patch (Duo-
DERM Extra Thin; Convatec, Princeton, NJ) and applied to the
Anti-Cytokine Treatment In Vivo and In Vitroshaved area (Herrick et al., 2000). As controls, MOG35-55, PLP139-
Mice were treated intraperitoneally with 1 mg of anti-IL-4 or anti-151, or OVA (Grade V, Sigma Chemical Co., St. Louis, MO) (100 g/
IL-10, or 0.5 mg of anti-TGF- or isotype-matched controls (in 300ml or 10 g/ml) in PBS, or PBS were used. The patch was left in place
l PBS) at 1 week intervals prior to (week 0) and during ECi (weeksfor 1 week. This was repeated for a second week. At the end of week
1 and 2) and for 2 weeks after disease induction (weeks 3 and 4).2 the patch was removed and EAE was induced by immunizing mice
Sorted naive CD4 T cells (5  105) were cocultured with APCs (2 subcutaneously in the flanks with Ac1-11 or PLP139-151 in complete
105) and Ac1-11 at 10 g/ml in the presence of 5  105 Ts cells andFreund’s adjuvant (CFA), followed by intravenous pertussis toxin
neutralizing monoclonal antibodies to IL-4, IL-10, TGF-, or theirinjection on the day of immunization and 2 days later.
isotype-matched Ig as controls (rat IgG1, mouse IgG1).
IFN- ELISAEAE Scoring
A numerical score was assigned to mice based on the severity of Sera were obtained from mice at day 0 (week 0, prior to skin patch-
ing), week 1 (1 week after skin patching), week 2 (end of 2 weeksthe disease symptom. 0  no disease; 1  limp tail; 2  weak tail
and partial hind limb paralysis; 3  total hind limb paralysis; 4  of skin patching), and weeks 3 to 6 (after EAE induction), pooled
from three different experiments, and frozen at 70	C until use.both hind limb and fore limb paralysis; 5  dead. Mice with a score
of 4 were euthanized. Supernatants were collected (at 24 and 48 hr, and day 5 and 14
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